Navigation Links
ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
Date:8/9/2012

EXTON, Pa., Aug. 9, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the second quarter ended June 30, 2012.

Since March 31, 2012, we:

  • Achieved $95 million in quarterly net product sales, including $77 million in worldwide net sales of Cinryze® (C1 esterase inhibitor [human]);
  • Received FDA approval of the Prior Approval Supplement (PAS) for industrial scale manufacturing for Cinryze;
  • Delivered positive cash flows from operations of $22 million during the second quarter;
  • Finished the quarter with cash, cash equivalents and short term investments of $472 million;
  • Recorded GAAP net loss of $4 million; attained non-GAAP adjusted net income of $7 million during the second quarter of 2012;
  • Repurchased an additional 1.1 million shares of our common stock at a cost of approximately $22 million during the second quarter;
  • Initiated a Phase 2 program to evaluate maribavir for the treatment of CMV infections in transplant recipients;
  • Announced that the FDA has placed a temporary clinical hold on development of Cinryze subcutaneous administration with Halozyme's rHuPH20 technology until further review;  and
  • Announced the FDA denial of the Vancocin Citizen Petition and subsequent introductions of generic oral vancomycin.
  • Net sales were $94.6 million for the second quarter ended June 30, 2012, as compared to $128.8 million in the comparative period of 2011. The decrease was the result of the impact of generic oral vancomycin entries into the market. Regarding Cinryze, the channel remained below normal levels from the end of the first quarter and as a result, the revenue reported is more reflective of demand.  The company anticipates that the levels of channel inventory will increase in the third and fourth quarters as additi
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
    2. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
    3. ViroPharma To Participate In The JMP Securities Healthcare Conference
    4. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
    5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    6. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
    7. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
    8. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
    9. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
    10. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
    11. GenVec Reports Second Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
    (Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses on ... the United States . Reimbursement analysis ... Thorough product analyses for more than 73 SMBG meters ...
    (Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
    Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
    (Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
    (Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
    (Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
    (Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience of ... has introduced its new collection of 2015 prom dresses, ... new prom outfits are guaranteed to contain the perfect ... specially designed for 2015. Anyone who wants to buy ... website before Jan. 26, 2015, the deadline of the ...
    (Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
    Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
    ... which suggests hormone suppression therapy could increase substantially ... free of the disease.Michel Bolla, a professor at ... suppressing the male hormone androgen, similar to the ... patients in advanced stages// of their prostate cancer, ...
    ... a good amount of fluids should be taken, in order ... far better than 'energy' drinks for keeping you hydrated during ... you'll be well aware of the need to keep your ... lot of so-called energy drinks around, which seem to promise ...
    ... proteins, which are protective substances, produced by the body ... the TB bacteria, researchers in the UK report. According ... journal Nature Medicine,// these heat-shock proteins, which are special ... times and bolster the immune system of the body. ...
    ... According to new study, a new type of antidepressant, ... anxiety disorder (SAD) people experience fear, anxiety and dread ... which can make both work //and social situations a ... mental health problems, like depression, and the condition can ...
    ... at the University of Texas, have shown that use of ... to 70 per cent of US women born since 1950 ... that use of the hormones in the Pill could raise ... failed to reveal a connection. The early Pill users are ...
    ... at the University of Texas has found that caffeine ... in preterm infants. Sleep apnea is a condition characterized ... infants. However, there is a growing concern over caffeine's ... Texas analyzed the effects of caffeine on cardiac output, ...
    Cached Medicine News:Health News:Hormone Therapy applicable for Prostate Cancer 2Health News:Caffeine reduces infant blood flow 2
    Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
    Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide smooth handle with polished finish....
    Smooth 90 degree jaws with locking screw maintain proper stretch of sleeve for securing silicone bands....
    Ergotec Vetriretinal Instrument System. Extra fine angled tips (3 mm). 20 ga. shaft tapering to 23 ga., 10 mm from tip. Overall length from rear rotation knob to tip....
    Medicine Products: